Total submissions: 8
| Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
|---|---|---|---|---|---|---|---|---|
| Gene |
RCV000593270 | SCV007537716 | likely pathogenic | not provided | 2025-09-25 | criteria provided, single submitter | clinical testing | Reported as a single heterozygous finding in a proband with emphysema, asthma, bronchitis and a history of smoking (PMID: 8364536); Canonical splice site variant predicted to result in a null allele in a gene for which loss of function is a known mechanism of disease; Not observed at significant frequency in large population cohorts (gnomAD); This variant is associated with the following publications: (PMID: 25525159, 8364536, 36451132, 29625052, 37277845) |
| Baylor Genetics | RCV000169461 | SCV004203125 | likely pathogenic | Alpha-1-antitrypsin deficiency | 2023-07-19 | criteria provided, single submitter | clinical testing | |
| Labcorp Genetics |
RCV000169461 | SCV002245454 | pathogenic | Alpha-1-antitrypsin deficiency | 2025-06-22 | criteria provided, single submitter | clinical testing | This sequence change affects a donor splice site in intron 2 of the SERPINA1 gene. It is expected to disrupt RNA splicing. Variants that disrupt the donor or acceptor splice site typically lead to a loss of protein function (PMID: 16199547), and loss-of-function variants in SERPINA1 are known to be pathogenic (PMID: 25425243). This variant is present in population databases (rs751235320, gnomAD 0.0009%). This variant has not been reported in the literature in individuals affected with SERPINA1-related conditions. ClinVar contains an entry for this variant (Variation ID: 189064). Studies have shown that disruption of this splice site alters SERPINA1 gene expression (PMID: 8364536). Algorithms developed to predict the effect of sequence changes on RNA splicing suggest that this variant may disrupt the consensus splice site. For these reasons, this variant has been classified as Pathogenic. |
| Eurofins Ntd Llc |
RCV000593270 | SCV000706472 | likely pathogenic | not provided | 2017-02-21 | criteria provided, single submitter | clinical testing | |
| Dr. |
RCV005889647 | SCV006837261 | not provided | Hepatocellular carcinoma | no classification provided | in vitro | ||
| Department of Laboratory Medicine and Genetics, |
RCV000169461 | SCV000608321 | pathogenic | Alpha-1-antitrypsin deficiency | 2014-12-08 | no assertion criteria provided | curation | |
| Counsyl | RCV000169461 | SCV000220891 | likely pathogenic | Alpha-1-antitrypsin deficiency | 2014-11-14 | no assertion criteria provided | literature only | This submission and the accompanying classification are no longer maintained by the submitter. For more information on current observations and classification, please contact variantquestions@myriad.com. |
| OMIM | RCV000019606 | SCV000039904 | other | PI NULL(WEST) | 2016-07-15 | no assertion criteria provided | literature only |